[US-헬스케어] 06/11 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate strong market momentum, primarily driven by the clinical success of its next-generation obesity pipeline, including retatrutide. The recent surge in share price reflects investor confidence in the company’s ability to maintain its leadership in the GLP-1 agonist market. Beyond its core weight-loss franchise, the company is strategically diversifying its portfolio, notably through significant capital allocation into the vaccine market. This dual-engine approach—maximizing high-growth metabolic therapeutics while securing long-term growth through new modalities—solidifies LLY’s position as a dominant force in the global biopharmaceutical sector.

Novo Nordisk’s recent regulatory milestone—securing EU backing for the oral version of Wegovy—marks a pivotal shift in the company’s competitive strategy. By transitioning from injectable to oral administration, Novo Nordisk is poised to significantly lower barriers to patient adherence and expand its Total Addressable Market (TAM).

Furthermore, the strategic expansion into the UAE as the first market outside the U.S. for its oral formulation underscores a robust global commercialization roadmap. While short-term price volatility persists due to supply chain constraints and profit-taking, the underlying fundamentals remain strong. The shift toward oral delivery is a “game-changer” that effectively addresses the logistical bottlenecks of current GLP-1 therapies, reinforcing the company’s long-term leadership in the obesity and metabolic disease sector.

Amgen (AMGN) is currently navigating a pivotal transition phase, balancing robust clinical momentum with long-term valuation concerns. The recent regulatory success of Imdelltra in Europe serves as a critical catalyst, reinforcing the company’s leadership in the oncology pipeline and offsetting potential headwinds from Tavneos market risks.

While the stock has delivered a strong 24% return over the past year, prompting questions regarding its current valuation, the company’s ability to sustain growth through its diversified portfolio remains intact. Investors should monitor the integration of recent acquisitions and the impact of capital allocation strategies, as confirmed by recent shareholder support for board governance, to determine if the current premium is justified for long-term holders.

UnitedHealth Group (UNH) is currently demonstrating strong operational resilience and strategic foresight. The recent commitment of $1.6 billion toward Artificial Intelligence (AI) integration is a critical catalyst, aimed at optimizing administrative workflows and enhancing long-term operational efficiency. Furthermore, the company’s proactive shift toward a more transparent pricing model within its Optum Rx segment addresses mounting regulatory scrutiny, effectively mitigating potential legislative headwinds. Despite institutional divestment, the combination of robust dividend growth and stabilized medical cost trends provides a compelling value proposition for long-term investors.

Pfizer (PFE) is currently navigating a critical transition period as it shifts focus from pandemic-era windfalls to long-term growth through its R&D pipeline and strategic acquisitions. While the company’s Q1 performance exceeded market expectations, the stock remains range-bound near the $26 level, reflecting investor skepticism regarding the speed of its revenue diversification.

The core investment thesis hinges on whether Pfizer’s recent advancements in vaccine technology and hematology can sufficiently offset the patent cliff and declining COVID-19 product sales. While the valuation appears attractive from a historical perspective, the market is demanding clearer evidence of sustained top-line growth before re-rating the stock. Investors should monitor the commercial execution of its new drug launches as the primary catalyst for a potential breakout.